Symbols / IRON Stock $70.03 +2.19% Disc Medicine, Inc.

Healthcare • Biotechnology • United States • NGM
IRON (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. John D. Quisel Esq., J.D., Ph.D.
Exch · Country NGM · United States
Market Cap 2.68B
Enterprise Value 1.92B
Income -241.60M
Sales —
FCF (ttm) -121.40M
Book/sh 18.03
Cash/sh 19.11
Employees 154
Insider 10d —
IPO Aug 12, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -9.35
PEG —
P/S —
P/B 3.88
P/C —
EV/EBITDA -7.26
EV/Sales —
Quick Ratio 23.45
Current Ratio 24.00
Debt/Eq 4.51
LT Debt/Eq —
EPS (ttm) -6.64
EPS next Y -7.49
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-05
ROA -22.67%
ROE -35.83%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 38.20M
Shs Float 33.23M
Insider Own 7.78%
Instit Own 105.77%
Short Float 16.92%
Short Ratio 13.79
Short Interest 5.54M
52W High 99.50
vs 52W High -29.62%
52W Low 40.00
vs 52W Low 75.08%
Beta 2.14
Impl. Vol. 48.63%
Rel Volume 1.26
Avg Volume 586.79K
Volume 741.89K
Target (mean) $100.17
Tgt Median $100.00
Tgt Low $75.00
Tgt High $128.00
# Analysts 12
Recom Strong_buy
Prev Close $68.53
Price $70.03
Change 2.19%
About

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$100.17
Mean price target
2. Current target
$70.03
Latest analyst target
3. DCF / Fair value
$-57.20
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$70.03
Low
$75.00
High
$128.00
Mean
$100.17

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-02 main Wells Fargo Overweight → Overweight $79
2026-02-27 main Truist Securities Buy → Buy $83
2026-02-17 main Stifel Buy → Buy $110
2026-02-17 main Cantor Fitzgerald Overweight → Overweight $125
2026-02-17 main BMO Capital Outperform → Outperform $100
2026-02-17 main Wedbush Outperform → Outperform $88
2026-02-17 main Wells Fargo Overweight → Overweight $78
2025-12-16 main Wells Fargo Overweight → Overweight $109
2025-11-10 main Truist Securities Buy → Buy $114
2025-10-30 main Morgan Stanley Overweight → Overweight $115
2025-10-17 main Raymond James Strong Buy → Strong Buy $108
2025-10-17 main Cantor Fitzgerald Overweight → Overweight $153
2025-10-17 main Wedbush Outperform → Outperform $110
2025-08-18 main Morgan Stanley Overweight → Overweight $90
2025-07-21 init Truist Securities — → Buy $86
2025-07-03 reit HC Wainwright & Co. Buy → Buy $118
2025-06-17 reit HC Wainwright & Co. Buy → Buy $118
2025-05-12 main BMO Capital Outperform → Outperform $120
2025-03-18 main Cantor Fitzgerald Overweight → Overweight $132
2025-03-03 main Scotiabank Sector Outperform → Sector Outperform $75
News
RSS: Latest IRON news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-14 FRANCHI JEAN M Chief Financial Officer — 6,657 $69.00 $460,834
2026-04-13 SAVAGE WILLIAM JACOB Officer — 5,731 $66.12 $380,449
2026-03-02 SAVAGE WILLIAM JACOB Officer — 7,378 $65.52 $486,069
2026-02-25 FRANCHI JEAN M Chief Financial Officer — 353 $69.06 $24,377
2026-02-18 FRANCHI JEAN M Chief Financial Officer — 11,156 $62.86 $719,727
2026-02-17 QUISEL JOHN D Chief Executive Officer — 13,264 $62.86 $833,775
2026-02-17 STEPHENSON PAMELA Officer — 5,531 $62.86 $347,679
2026-02-17 YU JONATHAN YEN-WEN Chief Operating Officer — 3,231 $62.86 $203,101
2026-02-17 SAVAGE WILLIAM JACOB Officer — 3,256 $62.86 $204,672
2026-02-17 KHARA RAHUL Officer — 2,853 $62.86 $179,340
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
236.02
+81.95%
129.72
+42.35%
91.12
+91.94%
47.48
Research And Development
170.64
+76.52%
96.67
+39.57%
69.26
+107.15%
33.44
Selling General And Administration
65.38
+97.83%
33.05
+51.18%
21.86
+55.73%
14.04
General And Administrative Expense
65.38
+97.83%
33.05
+51.18%
21.86
+55.73%
14.04
Salaries And Wages
36.84
+90.21%
19.37
+84.78%
10.48
—
Other Gand A
28.54
+108.62%
13.68
+20.23%
11.38
-18.93%
14.04
Total Expenses
236.02
+81.95%
129.72
+42.35%
91.12
+91.94%
47.48
Operating Income
-236.02
-81.95%
-129.72
-42.35%
-91.12
-91.94%
-47.48
Total Operating Income As Reported
-236.02
-81.95%
-129.72
-42.35%
-91.12
-91.94%
-47.48
EBITDA
-207.94
-92.05%
-108.27
-42.04%
-76.23
-60.87%
-47.39
Normalized EBITDA
-207.94
-92.05%
-108.27
-42.04%
-76.23
-61.08%
-47.33
Reconciled Depreciation
0.28
+80.13%
0.16
+56.00%
0.10
+12.36%
0.09
EBIT
-208.22
-92.03%
-108.43
-42.05%
-76.33
-60.78%
-47.48
Total Unusual Items
—
—
—
-0.06
Total Unusual Items Excluding Goodwill
—
—
—
-0.06
Net Income
-212.18
-94.03%
-109.36
-43.08%
-76.43
-63.22%
-46.83
Pretax Income
-211.82
-94.33%
-109.00
-42.80%
-76.33
-63.00%
-46.83
Net Non Operating Interest Income Expense
24.15
+16.57%
20.72
+40.03%
14.80
+1987.02%
0.71
Interest Expense Non Operating
3.61
+530.59%
0.57
0.00
—
Net Interest Income
24.15
+16.57%
20.72
+40.03%
14.80
+1987.02%
0.71
Interest Expense
3.61
+530.59%
0.57
0.00
—
Interest Income Non Operating
27.76
+30.38%
21.29
+43.89%
14.80
+1987.02%
0.71
Interest Income
27.76
+30.38%
21.29
+43.89%
14.80
+1987.02%
0.71
Other Income Expense
0.04
+2350.00%
-0.00
+0.00%
-0.00
+96.72%
-0.06
Other Non Operating Income Expenses
0.04
+2350.00%
-0.00
+0.00%
-0.00
—
Gain On Sale Of Security
—
—
—
-0.06
Tax Provision
0.36
+1.69%
0.35
+258.59%
0.10
0.00
Tax Rate For Calcs
0.00
+0.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-212.18
-94.03%
-109.36
-43.08%
-76.43
-63.22%
-46.83
Net Income From Continuing Operation Net Minority Interest
-212.18
-94.03%
-109.36
-43.08%
-76.43
-63.22%
-46.83
Net Income From Continuing And Discontinued Operation
-212.18
-94.03%
-109.36
-43.08%
-76.43
-63.22%
-46.83
Net Income Continuous Operations
-212.18
-94.03%
-109.36
-43.08%
-76.43
-63.22%
-46.83
Normalized Income
-212.18
-94.03%
-109.36
-43.08%
-76.43
-63.43%
-46.77
Net Income Common Stockholders
-212.18
-94.03%
-109.36
-43.08%
-76.43
-63.22%
-46.83
Diluted EPS
—
-3.96
-15.79%
-3.42
+92.41%
-45.05
Basic EPS
—
-3.96
-15.79%
-3.42
+92.41%
-45.05
Basic Average Shares
—
27.61
+23.71%
22.32
+2046.81%
1.04
Diluted Average Shares
—
27.61
+23.71%
22.32
+2046.81%
1.04
Diluted NI Availto Com Stockholders
-212.18
-94.03%
-109.36
-43.08%
-76.43
-63.22%
-46.83
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
806.88
+62.42%
496.77
+34.99%
368.00
+83.81%
200.21
Current Assets
803.90
+62.86%
493.62
+34.99%
365.66
+84.22%
198.49
Cash Cash Equivalents And Short Term Investments
791.15
+61.50%
489.88
+35.93%
360.38
+85.18%
194.61
Cash And Cash Equivalents
91.14
-52.64%
192.43
-46.60%
360.38
+85.18%
194.61
Other Short Term Investments
700.01
+135.34%
297.45
0.00
—
Prepaid Assets
—
—
5.28
+36.08%
3.88
Restricted Cash
—
—
—
—
Other Current Assets
12.75
+241.35%
3.73
-29.28%
5.28
+36.08%
3.88
Total Non Current Assets
2.98
-5.60%
3.16
+35.30%
2.33
+36.17%
1.71
Net PPE
2.25
-2.80%
2.32
+10.48%
2.10
+31.41%
1.60
Gross PPE
2.25
-2.80%
2.32
-1.07%
2.35
+34.54%
1.74
Accumulated Depreciation
—
-0.40
-63.67%
-0.24
-68.97%
-0.14
Properties
—
0.00
0.00
—
Machinery Furniture Equipment
—
0.59
+41.20%
0.41
+32.59%
0.31
Other Properties
2.25
-2.80%
2.32
+20.21%
1.93
+34.97%
1.43
Leases
—
0.57
0.00
—
Non Current Deferred Assets
—
—
—
—
Other Non Current Assets
0.73
-13.37%
0.84
+258.12%
0.23
+101.72%
0.12
Total Liabilities Net Minority Interest
67.05
+26.07%
53.19
+132.51%
22.88
-3.09%
23.61
Current Liabilities
36.64
+57.15%
23.32
+8.76%
21.44
-5.04%
22.58
Payables And Accrued Expenses
23.39
+46.40%
15.97
+6.61%
14.98
-19.65%
18.65
Payables
9.02
+13.46%
7.95
-37.07%
12.63
-21.86%
16.16
Accounts Payable
9.02
+13.46%
7.95
-37.07%
12.63
-21.86%
16.16
Current Accrued Expenses
14.37
+79.02%
8.03
+240.85%
2.35
-5.27%
2.49
Pensionand Other Post Retirement Benefit Plans Current
12.64
+75.32%
7.21
+24.54%
5.79
+59.81%
3.62
Current Debt And Capital Lease Obligation
0.61
+370.00%
0.13
-80.45%
0.67
+116.61%
0.31
Current Debt
—
—
—
—
Other Current Borrowings
—
—
—
—
Current Capital Lease Obligation
0.61
+370.00%
0.13
-80.45%
0.67
+116.61%
0.31
Other Current Liabilities
—
—
—
—
Total Non Current Liabilities Net Minority Interest
30.41
+1.81%
29.87
+1980.08%
1.44
+39.82%
1.03
Long Term Debt And Capital Lease Obligation
30.41
+1.81%
29.87
+1980.08%
1.44
+39.82%
1.03
Long Term Debt
29.16
+2.96%
28.32
—
—
Long Term Capital Lease Obligation
1.25
-19.06%
1.55
+7.80%
1.44
+39.82%
1.03
Other Non Current Liabilities
—
—
—
—
Preferred Securities Outside Stock Equity
—
—
—
0.00
Stockholders Equity
739.83
+66.78%
443.59
+28.53%
345.12
+95.43%
176.60
Common Stock Equity
739.83
+66.78%
443.59
+28.53%
345.12
+95.43%
176.60
Capital Stock
0.00
+33.33%
0.00
+50.00%
0.00
+0.00%
0.00
Common Stock
0.00
+33.33%
0.00
+50.00%
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
37.89
+26.87%
29.87
+22.60%
24.36
+39.97%
17.40
Ordinary Shares Number
37.89
+26.87%
29.87
+22.60%
24.36
+39.97%
17.40
Additional Paid In Capital
1,249.04
+68.49%
741.30
+38.88%
533.76
+84.81%
288.81
Retained Earnings
-510.19
-71.20%
-298.00
-57.97%
-188.65
-68.11%
-112.22
Gains Losses Not Affecting Retained Earnings
0.96
+233.91%
0.29
0.00
—
Other Equity Adjustments
0.96
+233.91%
0.29
—
—
Total Equity Gross Minority Interest
739.83
+66.78%
443.59
+28.53%
345.12
+95.43%
176.60
Total Capitalization
768.99
+62.95%
471.91
+36.74%
345.12
+95.43%
176.60
Working Capital
767.26
+63.14%
470.30
+36.63%
344.22
+95.68%
175.91
Invested Capital
768.99
+62.95%
471.91
+36.74%
345.12
+95.43%
176.60
Total Debt
31.02
+3.41%
30.00
+1327.89%
2.10
+57.50%
1.33
Capital Lease Obligations
1.86
+11.08%
1.68
-20.13%
2.10
+57.50%
1.33
Net Tangible Assets
739.83
+66.78%
443.59
+28.53%
345.12
+95.43%
176.60
Tangible Book Value
739.83
+66.78%
443.59
+28.53%
345.12
+95.43%
176.60
Derivative Product Liabilities
—
—
—
—
Interest Payable
—
—
—
—
Preferred Stock Equity
—
—
—
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-180.39
-92.06%
-93.93
-27.86%
-73.46
-73.87%
-42.25
Cash Flow From Continuing Operating Activities
-180.39
-92.06%
-93.93
-27.86%
-73.46
-73.87%
-42.25
Net Income From Continuing Operations
-212.18
-94.03%
-109.36
-43.08%
-76.43
-63.22%
-46.83
Depreciation Amortization Depletion
0.28
+80.13%
0.16
+56.00%
0.10
+12.36%
0.09
Depreciation
—
—
—
—
Depreciation And Amortization
0.28
+80.13%
0.16
+56.00%
0.10
+12.36%
0.09
Other Non Cash Items
2.16
+305.82%
0.53
+83.79%
0.29
+37.44%
0.21
Stock Based Compensation
34.34
+104.22%
16.82
+204.07%
5.53
+164.72%
2.09
Operating Gains Losses
—
—
—
0.06
Gain Loss On Investment Securities
—
—
—
0.06
Gain Loss On Sale Of PPE
—
—
—
—
Change In Working Capital
3.53
+9.13%
3.23
+209.41%
-2.95
-238.96%
2.12
Change In Prepaid Assets
-8.92
-667.92%
1.57
+234.73%
-1.17
-431.25%
0.35
Change In Payables And Accrued Expense
12.26
+469.00%
2.15
+224.35%
-1.73
-185.45%
2.03
Change In Accrued Expense
11.19
+63.72%
6.84
+240.44%
2.01
+33.69%
1.50
Change In Payable
1.07
+122.86%
-4.68
-25.13%
-3.74
-811.22%
0.53
Change In Account Payable
1.07
+122.86%
-4.68
-25.13%
-3.74
-811.22%
0.53
Change In Other Working Capital
—
—
—
—
Change In Other Current Assets
—
—
0.00
-100.00%
0.06
Change In Other Current Liabilities
0.19
+137.58%
-0.49
-816.67%
-0.05
+83.07%
-0.32
Investing Cash Flow
-394.30
-34.88%
-292.33
-328362.92%
-0.09
+41.06%
-0.15
Cash Flow From Continuing Investing Activities
-394.30
-34.88%
-292.33
-328362.92%
-0.09
+41.06%
-0.15
Net PPE Purchase And Sale
-0.93
-84.75%
-0.51
-467.42%
-0.09
+41.06%
-0.15
Purchase Of PPE
-0.93
-84.75%
-0.51
-467.42%
-0.09
+41.06%
-0.15
Sale Of PPE
—
—
—
—
Capital Expenditure
-0.93
-84.75%
-0.51
-467.42%
-0.09
+41.06%
-0.15
Net Investment Purchase And Sale
-393.37
-34.79%
-291.83
0.00
—
Purchase Of Investment
-849.59
-119.74%
-386.63
0.00
—
Sale Of Investment
456.22
+381.24%
94.80
0.00
—
Financing Cash Flow
473.41
+116.85%
218.31
-8.80%
239.38
+60.68%
148.98
Cash Flow From Continuing Financing Activities
473.41
+116.85%
218.31
-8.80%
239.38
+60.68%
148.98
Net Issuance Payments Of Debt
0.00
-100.00%
28.99
0.00
—
Issuance Of Debt
0.00
-100.00%
28.99
0.00
—
Repayment Of Debt
—
—
—
—
Long Term Debt Issuance
0.00
-100.00%
28.99
0.00
—
Long Term Debt Payments
—
—
—
—
Net Long Term Debt Issuance
0.00
-100.00%
28.99
0.00
—
Net Common Stock Issuance
450.11
+140.31%
187.30
-5.92%
199.08
+272.11%
53.50
Proceeds From Stock Option Exercised
23.30
+581.74%
3.42
-91.52%
40.30
+18302.28%
0.22
Net Other Financing Charges
—
-1.39
—
95.26
Changes In Cash
-101.28
+39.69%
-167.94
-201.28%
165.83
+55.60%
106.58
Beginning Cash Position
192.67
-46.57%
360.62
+85.13%
194.79
+120.82%
88.21
End Cash Position
91.39
-52.57%
192.67
-46.57%
360.62
+85.13%
194.79
Free Cash Flow
-181.33
-92.02%
-94.43
-28.39%
-73.55
-73.46%
-42.40
Interest Paid Supplemental Data
2.79
+1311.62%
0.20
0.00
—
Income Tax Paid Supplemental Data
—
0.30
+166.96%
0.11
0.00
Amortization Of Securities
-8.52
-60.61%
-5.30
0.00
—
Common Stock Issuance
450.11
+140.31%
187.30
-5.92%
199.08
+272.11%
53.50
Issuance Of Capital Stock
450.11
+140.31%
187.30
-5.92%
199.08
+272.11%
53.50
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category